Absci's AI-Designed Hair-Loss Drug Clears a Safety Hurdle — But Can a Company Burning $100M a Year Survive Long Enough to Prove It Works?

Shares of Absci Corp jumped 9.8% to $8.83 after CEO Sean McClain presented updated safety results from the company's lead hair-loss drug at the Morgan Stanley Global Healthcare Conference on September 16. The presentation took place at Morgan Stanley's 24th Annual Global Healthcare Conference. The rally puts investors squarely in front of a bigger question: whether clean safety data alone justifies the stock's roughly $1.5 billion market cap for a company with virtually no revenue.

• No Serious Side Effects Is Good News, But the Hard Part Hasn't Started Yet. In 32 healthy adults given single ascending IV doses up to 1,800 mg, the drug showed a favorable safety profile with no serious adverse events, mostly mild treatment-emergent events, and an estimated half-life of at least 65 days. That long half-life is significant because it means patients could need only two or three injections over six months — a major convenience edge over daily pills like finasteride. But safety in healthy volunteers is the lowest bar in drug development. Efficacy proof still lies ahead , with interim proof-of-concept data — showing whether the drug actually regrows hair — expected later this year, and a full 26-week readout in early 2027.

• Hair Loss Is a Crowded Race With Well-Funded Rivals. The FDA hasn't approved a single new molecular treatment for pattern baldness since finasteride in 1997, and that 30-year innovation gap is finally closing. Absci isn't alone. A competing antibody targeting the same prolactin receptor is already in Phase 2 trials.

Pelage Pharmaceuticals, backed by $120 million in Series B funding, is launching Phase 3 trials in 2026 for a different approach entirely. Absci must show its AI-designed drug is differentiated enough to win in a rapidly filling field.

• Eli Lilly's Backing Buys Time, Not Certainty. Absci completed a $100 million offering, including a $40 million strategic equity investment from Eli Lilly. That cash, combined with existing reserves, is projected to fund operations into the second half of 2028. But the company posted a net loss of $115.2 million in fiscal 2025 on just $2.8 million in revenue. A price-to-sales ratio above 290x means investors are paying almost entirely for a future that hinges on clinical data not yet generated.

• The Real Catalyst Is Months Away. Today's pop reflects renewed attention, not new efficacy evidence. Absci has deprioritized its oncology programs , concentrating nearly all its bets on this single drug for hair loss and endometriosis, a condition affecting an estimated 9 million U.S. women with no FDA-approved disease-modifying therapy. The proof-of-concept readout later this year will be the make-or-break moment. Until then, the stock trades on hope — informed hope, perhaps, but hope nonetheless.